Division of Neurosurgery, Department of Surgery, Thammasat University Hospital, Faculty of Medicine, Thammasat University, Pathumthani, Thailand.
J Int Med Res. 2023 Nov;51(11):3000605231212316. doi: 10.1177/03000605231212316.
Current evidence supporting the use of continuous intravenous labetalol for blood pressure (BP) control in neurosurgical patients is limited. This study aims to assess the efficacy and safety of labetalol in neurosurgical patients and identify potential contributing factors to these outcomes.
We retrospectively reviewed the medical records of neurosurgical patients who received continuous labetalol infusion for BP control. Efficacy was assessed based on the time needed to achieve the target BP (systolic BP ≤ 140 mmHg or diastolic BP ≤ 90 mmHg). Safety was assessed according to adverse events that occurred during labetalol administration. Factors associated with efficacy and safety were analyzed using a logistic regression model.
Among 79 patients enrolled in this study, 47 (59.49%) achieved the target BP within 1 hour (early response). No factors were significantly associated with an early response. Hypotension was observed in 11 patients (13.9%), and bradycardia was observed in 8 patients (10.1%). Hypotension was significantly associated with patient age and motor impairment, while bradycardia was significantly associated with diabetes mellitus.
The efficacy and safety profiles of labetalol infusion suggest this treatment as a promising option for BP control in neurosurgical patients.
目前支持在神经外科患者中使用持续静脉滴注拉贝洛尔控制血压（BP）的证据有限。本研究旨在评估拉贝洛尔在神经外科患者中的疗效和安全性，并确定这些结果的潜在影响因素。
我们回顾性分析了接受持续拉贝洛尔输注以控制血压的神经外科患者的病历。根据达到目标血压（收缩压≤140mmHg 或舒张压≤90mmHg）所需的时间来评估疗效。根据拉贝洛尔给药期间发生的不良事件评估安全性。使用逻辑回归模型分析与疗效和安全性相关的因素。
在这项研究中，共纳入了 79 名患者，其中 47 名（59.49%）在 1 小时内达到目标血压（早期反应）。没有任何因素与早期反应显著相关。11 名患者（13.9%）出现低血压，8 名患者（10.1%）出现心动过缓。低血压与患者年龄和运动障碍显著相关，而心动过缓与糖尿病显著相关。
拉贝洛尔输注的疗效和安全性特征表明，这种治疗方法是神经外科患者控制血压的一种有前途的选择。
